ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $28.00

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target lifted by JPMorgan Chase & Co. from $21.00 to $28.00 in a research report released on Monday morning, FlyOnTheWall reports. Other research analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their price target on shares of ACADIA Pharmaceuticals from […]

Related Keywords

Canada ,China ,James Kihara ,Brendan Teehan ,Citigroup ,Cm Bidwell Associates Ltd ,Pharmaceuticals Company Profile ,Pharmaceuticals Daily ,Exchange Traded Concepts ,Royal Bank ,Credit Suisse Group ,Securities Exchange Commission ,Acadia Pharmaceuticals ,China Universal Asset Management Co ,Pharmaceuticals Stock Performance ,Nisa Investment Advisors ,Jpmorgan Chase Co ,Pharmaceuticals Inc ,Free Report ,Suisse Group ,Moderate Buy ,Get Free Report ,Exchange Commission ,Universal Asset Management ,Investment Advisors ,Traded Concepts ,Nasdaq Acad ,Facad ,Medical ,Boost Price Target ,